舒洛地特联合替米沙坦治疗原发性膜性肾病的效果及对肝肾功能指标的影响  

Effect of Sulodexide Combined with Telmisartan in the Treatment of Primary Membranous Nephropathy and Its Influence on Liver and Renal Function Indexes

作　　者：刘玉翠[1] 李小清 LIU Yucui;LI Xiaoqing(Zhijiang People’s Hospital,Zhijiang 443200,China;不详)

机构地区：[1]枝江市人民医院,湖北枝江443200

出　　处：《中外医学研究》2021年第28期131-134,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

摘　　要：目的:探讨舒洛地特联合替米沙坦治疗原发性膜性肾病的效果及对肝肾功能指标的影响。方法:选取2019年12月-2020年12月笔者所在医院收治的80例原发性膜性肾病患者为研究对象。根据入院时间先后顺序将其分为研究组与对照组,每组40例。两组均实施常规治疗,在此基础上,对照组给予舒洛地特治疗,观察组给予舒洛地特联合替米沙坦治疗。比较两组治疗效果、不良反应及治疗前后肝肾功能指标。结果:研究组治疗总有效率为92.50%,高于对照组的70.00%,差异有统计学意义(P<0.05)。研究组不良反应发生率为12.50%,对照组不良反应发生率为10.00%,组间比较差异无统计学意义(P>0.05)。两组治疗前后ALT、AST比较差异均无统计学意义(P>0.05)。治疗前,两组血浆白蛋白水平比较差异无统计学意义(P>0.05);治疗后,两组血浆白蛋白水平均明显高于治疗前,且研究组明显高于对照组,差异有统计学意义(P<0.05)。治疗后,两组24 h尿蛋白定量、Scr、Cys-C、BUN、eGFR水平均较治疗前明显改善,且研究改善程度大于对照组,差异有统计学意义(P<0.05)。结论:舒洛地特联合替米沙坦治疗原发性膜性肾病的效果较好,其可有效改善患者的肝肾功能指标,且安全性较高,值得临床推广与应用。Objective:To investigate the effect of Sulodexide combined with Telmisartan in the treatment of primary membranous nephropathy and its influence on liver and renal function indexes.Method:From December 2019 to December 2020,80 patients with primary membranous nephropathy admitted in our hospital were selected as the research objects.They were divided into the study group and the control group according to the order of admission time,with 40 cases in each group.Both groups were treated with conventional treatment.On this basis,the control group was treated with Sulodexide,and the study group was treated with Sulodexide combined with Telmisartan.The treatment effect,adverse reactions,liver and renal function indexes before and after treatment were compared between the two groups.Result:The total effective rate of the study group was 92.50%,which was higher than 70.00% of the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was 12.50%,the incidence of adverse reactions in the control group was 10.00%.There was no significant difference between the groups(P>0.05).There were no significant differences in ALT and AST between the two groups before and after treatment(P>0.05).There was no significant difference in the plasma albumin level between the two groups before treatment(P>0.05).After treatment,the plasma albumin levels of the two groups were significantly higher than those before treatment,and the study group was significantly higher than the control group,the differences were statistically significant(P<0.05).After treatment,the 24 h urine protein quantification,Scr,Cys-C,BUN and eGFR levels in the two groups were significantly improved compared with those before treatment,and the improvement degree in the study group were greater than that in the control group,the differences were statistically significant(P<0.05).Conclusion:Sulodexide combined with Telmisartan has a good effect in the treatment of primary membranous nephropathy,which can e

关 键 词：原发性膜性肾病 舒洛地特 替米沙坦 肝肾功能 

分 类 号：R692[医药卫生—泌尿科学]